Collegium Pharmaceutical (NASDAQ:COLL) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
Earnings and Valuation
This table compares Collegium Pharmaceutical and Clovis Oncology’s top-line revenue, earnings per share and valuation.
||Earnings Per Share
Collegium Pharmaceutical has higher earnings, but lower revenue than Clovis Oncology. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Collegium Pharmaceutical has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500.
This is a breakdown of recent ratings for Collegium Pharmaceutical and Clovis Oncology, as provided by MarketBeat.com.
||Strong Buy Ratings
Collegium Pharmaceutical presently has a consensus target price of $32.67, suggesting a potential upside of 71.48%. Clovis Oncology has a consensus target price of $57.05, suggesting a potential upside of 165.11%. Given Clovis Oncology’s higher possible upside, analysts plainly believe Clovis Oncology is more favorable than Collegium Pharmaceutical.
This table compares Collegium Pharmaceutical and Clovis Oncology’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Collegium Pharmaceutical beats Clovis Oncology on 7 of the 12 factors compared between the two stocks.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
About Clovis Oncology
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.